Global Post-Polycythemia Vera Myelofibrosis Market is segmented By Type (Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, Others), By Application (Hospital, Clinic, Others), By Region (North America, Europe, South America, Asia-Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global "Post-Polycythemia Vera Myelofibrosis Market" is estimated to reach at a high CAGR during the forecast period (2024-2031).
Post-polycythemia vera myelofibrosis is a form of the myeloproliferative neoplasm, and it has also been called chronic idiopathic myelofibrosis. It is characterized by blood cells like white blood cells increasing in number, but thrombocytes decreasing, and platelet count gets lower than normal.
Market Dynamics
Next-generation sequencing in myeloproliferative neoplasms (MPNs) is expected to drive the market's growth.
According to the article, on 6 August 2020. The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in the predominantly epigenetic regulator, RNA splicing and signaling pathway genes. These molecular mutations are a sign of diagnostic, prognostic, and therapeutic assessment in patients with MPNs. Moreover, next-generation sequencing (NGS) has identified multiple somatic mutations in MPNs and has contributed substantially to our understanding of disease pathogenesis, highlighting the role of clonal evolution in disease progression. In addition, disease prognostication has expanded from encompassing only clinical decision-making to include genomics in prognostic scoring systems. Thus, from the above statements, the market's growth is expected to drive in the forecast period.
Side Effects associated with Durvalumab (Intravenous Route) are expected to hamper the market's growth.
According to the Mayo Clinic, Durvalumab injection is used to treat non-small cell lung cancer (NSCLC) that has not spread and cannot be removed by surgery. It is given to patients who have received other cancer medicines (e.g., platinum) and radiation treatment for their NSCLC.
Along with its needed effects, it has some unwanted effects. Although not all of these side effects may occur, they may need medical attention if they do occur. It includes side effects such as Bladder pain, bloating or swelling of the face, arms, hands, lower legs, or feet, bloody or cloudy urine, depressed mood, difficulty during urination, difficulty having a bowel movement, dry skin and hair, feeling cold and others. Thus, from the above statements, the market is expected to get hampered in the forecast period.
COVID-19 Impact Analysis
The coronavirus disease 2019 (COVID-19) pandemic has caused overwhelming challenges in healthcare worldwide. Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm identified by abundant red cell production leading to a broad range of symptoms that compromise patients' quality of life and productivity, leading to post-PV myelofibrosis or in the development of second cancers.
Moreover, the COVID-19 pandemic has impacted practically every phase of cancer care and research, from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research. It has also spurred creative solutions to challenges in clinical care. Additionally, research into the new disease is benefiting from insights gained over years of cancer research. Further researches are needed to recognize the advanced planning and rapid responses to reduce the impact of the pandemic as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.
Segment Analysis
Durvalumab segment is expected to hold the largest market share in this market segment.
Durvalumab segment has accounted for the largest market share in 2020. The growth of the segment is benefited to treat PPV-MF. It interferes with the activity of the human immune system by binding specific proteins on T cells and B cells, which are called immunoglobulins. The interference reduces the proliferation of both cells. Moreover, it also blocks kidney inflammation caused due to high levels of uric acid in the bloodstream that cause gout pain or crystals formation in kidneys and other tissues such as joints and muscles, where it can lead to arthritis pain and inflammation. Thus, from the above statements, the segment is expected to boost in the forecast period.
Hospital segment is expected to hold the largest market share in this market segment.
The hospital segment has accounted for the largest market share in 2020. The segment's growth is attributed to the increased incidence or prevalence of hematological malignancies and the requirement for stringent care protocols. The hospitals use ground zero for the treatment process where patients undergo chemotherapy with stem cell transplantation which requires high-level expertise and specialized equipment. Thus, from the above statements, the market is expected to drive in the forecast period.
Geographical Share
North America region holds the largest market share in the global post-polycythemia vera myelofibrosis (PPV-MF) market.
North America dominated the market with a revenue share in 2020. The segment's growth is attributed to a high prevalence of hematological malignancies and stringent care protocol requirements. For instance, according to the Leukemia and Lymphoma Society, Approximately every 3 minutes, one person in the United States (US) is diagnosed with blood cancer. An estimated combined total of 178,520 people in the US is expected to be diagnosed with leukemia, lymphoma or myeloma in 2020.
Moreover, new cases of leukemia, lymphoma and myeloma are expected to account for 9.9 percent of the estimated 1,806,590 new cancer cases diagnosed in the US in 2020. In addition, the growth will also be driven by an increasing number of stem cell transplants requiring specialized equipment, expertise, and hospitals with oncology facilities at ground zero and regular follow-up programs. Thus, from the above statements, the North American region is accounted for the largest market share in the forecast period.
Competitive Landscape
The post-polycythemia vera myelofibrosis (PPV-MF) market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AbbVie Inc, JW Pharmaceutical Corp, F. Hoffmann-La Roche Ltd, Celgene Corp, Italfarmaco SpA, Merck & Co Inc, Novartis AG, NS Pharma Inc, Gilead Sciences Inc and MEI Pharma Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the post-polycythemia vera myelofibrosis (PPV-MF) market globally.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Key Companies to Watch
Italfarmaco SpA:
Overview:
Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and participated companies. Italfarmaco was established in 1938. Moreover, it employs over 3000 people with an annual sales turnover of over 700 million euros. The Group has modern and sophisticated industrial plants where it manufactures medicinal specialties according to the highest quality standard. It is particularly outstanding for its commitment to research, mainly oriented towards the cardiovascular area and diseases associated with disorders of the immuno-oncologic system.
Product Portfolio:
Italfarmaco SpA has continuously set new standards for continuous manufacturing of therapeutic content such as cardiovascular, immuno-oncologic, gynecological, osteoporosis and neurologic area. For instance, Givinostat.
The global post-polycythemia vera myelofibrosis (PPV-MF) market report would provide an access to an approx.47 market data table, 43 figures and 180 pages.
